EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Hepatitis C Virus Genotype 5 Variability in Treatment-Naïve Patients in South Africa

Tshegofatso K Maunye, Maemu P Gededzha, Jason T Blackard, Johnny N Rakgole, Selokela G Selabe

Intervirology · 2023

DOI: 10.1159/000528178 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Intervirology, 2023. Verfasst von Tshegofatso K Maunye und 4 weiteren Autor:innen. Beteiligte Einrichtung: HIV and Hepatitis Research Unit, Department of Virology, Sefako Makgatho Health Sciences University, Pretoria, South Africa. Hauptthemen laut MEDLINE: Hepatitis C, Chronic, Hepatitis C. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Hepatitis C virus (HCV) genotype 5 was originally identified in South Africa, where it represents 35–60% of all HCV infections. There are limited data on resistance-associated variants (RAVs) in South Africa. Thus, we investigated variability within the NS3/NS4A, NS5A, and NS5B genes of treatment-naïve individuals with HCV genotype 5 infection at the Dr. George Mukhari Academic Hospital (DGMAH) in Pretoria, South Africa.

Methods

Nested PCR was performed to amplify the NS3/4A, NS5A, and NS5B genes. RAVs were evaluated using the Geno2pheno tool.

Results

In the NS3/4A gene, F56S and T122A were detected in one sample each. The D168E mutation was detected in 7 samples. Within the NS5A gene, the T62M mutation was detected in 2 individuals. In the NS5B gene, 8 of 12 individuals (67%) had the A421V mutation, while all 12 individuals (100%) had the S486A mutation.

Discussion

RAVs were detected frequently among treatment-naïve individuals with HCV genotype 5 infection in South Africa. Thus, resistance testing may be prudent when initiating treatment of patients with genotype 5 infection. Additional population-based studies are needed to understand the prevalence of these RAVs during HCV genotype 5 infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis C, ChronicHepatitis CHumansHepacivirusAntiviral AgentsSouth AfricaGenotypeDrug Resistance, ViralViral Nonstructural Proteins

Stichwörter der Autor:innen

AfricaDrug resistanceGenotypeHepatitis C virus

Substanzen

Antiviral AgentsViral Nonstructural Proteins

Autor:innen und Institutionen

  • HIV and Hepatitis Research Unit, Department of Virology, Sefako Makgatho Health Sciences University, Pretoria, South Africa.
  • National Health Laboratory Service, Pretoria, South Africa.
  • Department of Immunology, Faculty of Health Sciences, University of Witwatersrand and National Health Laboratory Service, Johannesburg, South Africa.
  • HIV and Hepatitis Research Unit, Department of Virology, Sefako Makgatho Health Sciences University, Pretoria, South Africa, jason.blackard@uc.edu.
  • Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA, jason.blackard@uc.edu.

Zitieren

APA

Maunye, T. K., Gededzha, M. P., Blackard, J. T., Rakgole, J. N., & Selabe, S. G. (2023). Hepatitis C Virus Genotype 5 Variability in Treatment-Naïve Patients in South Africa. Intervirology. https://doi.org/10.1159/000528178

Vancouver

Maunye TK, Gededzha MP, Blackard JT, Rakgole JN, Selabe SG. Hepatitis C Virus Genotype 5 Variability in Treatment-Naïve Patients in South Africa. Intervirology. 2023. doi:10.1159/000528178

BibTeX
@article{Maunye2023,
  author = {Maunye, Tshegofatso K and Gededzha, Maemu P and Blackard, Jason T and Rakgole, Johnny N and Selabe, Selokela G},
  title = {Hepatitis C Virus Genotype 5 Variability in Treatment-Naïve Patients in South Africa},
  journal = {Intervirology},
  year = {2023},
  doi = {10.1159/000528178}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche